TTFields — Tumor Treating Fields (Optune)

Tumor Treating Fields (TTFields) are alternating electric fields in the intermediate-frequency range, applied to a tumour region through arrays worn on the skin. Unlike the historical “frequency” devices in this Electromagnetic family, TTFields have a defined dose (field intensity, frequency, exposure hours), a worked-out mechanism (interference with the mitotic spindle and cytokinesis in dividing cells), and a body of clinical-trial evidence. This entry grades the cleared oncologic use; it is not a longevity device, and the broader “electric fields for general health” extrapolation is kept separate and ungraded.

Mechanism — real, dosed biophysics

TTFields exploit the fact that dividing cells are physically vulnerable during mitosis. Intermediate-frequency fields (~200 kHz for GBM) exert forces on polar intracellular structures — tubulin/microtubule assembly and the cleavage furrow — disrupting spindle formation and cytokinesis selectively in cells that are dividing, while sparing most quiescent tissue. Dose is governed by field intensity at the tumour, frequency tuned to cell type, and daily wear time (compliance is itself prognostic). Delivery is locoregional and noninvasive via four transducer arrays and a portable field generator with patient-specific array layout (NovoTAL planning). This is a measurable physical dose acting on a named target — the defining contrast with the “resonance/frequency” doctrines elsewhere in this family.

Claim vs evidence — why A/B, not A flat

The pivotal anchor is the EF-14 phase III randomized trial in newly diagnosed glioblastoma: 695 patients, median overall survival 19.4 vs 16.6 months for TTFields + temozolomide vs temozolomide alone, with progression-free survival improved by roughly three months (Stupp et al., JAMA 2017). That is a positive, registration-grade RCT with an overall-survival endpoint — the strongest tier of evidence, hence the A component for this indication. The grade is held at A/B rather than flat A for honest reasons kept on the page: the absolute median benefit is modest (~2.8 months); the trial was open-label by device necessity, which has drawn methodological debate; and the newer indications — pleural mesothelioma and post-platinum metastatic NSCLC (LUNAR) — rest on smaller or more recent evidence than the GBM pivotal. Evidence-supported, with the maturity of support varying by indication: that is what the dual badge encodes.

Why this tier — and the contrast that defines the family

TTFields sit at the top of the Electromagnetic family on the evidence axis, directly opposite the Lakhovsky MWO and Mishin Coil entries and the Rife doctrine in the information family. The surface idea looks superficially similar — “tuned electromagnetic frequencies act on cells.” The difference is everything this atlas grades on: TTFields specify a field intensity, a frequency matched to a measured cellular target, an exposure dose, and a positive controlled trial with a survival endpoint; the frequency-coil tradition specifies a mechanism that contradicts physics and has no controlled efficacy data. The Rife record already names TTFields as the legitimate cousin; this entry completes that pairing from the other side. Keep the real mechanism and the trial; the resemblance to “frequency healing” is nominal, not evidentiary.

Regulatory — cleared, and here the clearance is backed by evidence

Registration is never proof of efficacy in this atlas — but TTFields are one of the entries where the clearance and the evidence point the same way. FDA premarket approval: recurrent glioblastoma (2011), newly diagnosed glioblastoma with maintenance temozolomide (2015; second-generation Optune Gio cleared 2016), pleural mesothelioma with chemotherapy (Optune Lua), and post-platinum metastatic NSCLC with PD-1/PD-L1 inhibitor or docetaxel (2024, LUNAR). Approved in the US, Canada, China, Israel, Japan, and Australia; CE-marked in the EU for grade 4 glioma. The honest caveat is scope: clearance is indication-specific and oncologic — it is not a clearance for “anti-ageing” or general wellness use.

Keep vs set aside

Keep: the cleared oncologic mechanism — intermediate-frequency alternating electric fields disrupting mitosis, with a positive phase III survival trial in GBM and a defined, compliance-dependent dose. Set aside: any extrapolation beyond the cleared indications — longevity, general “cellular health,” or “electric-field therapy” framing untethered from the dosed oncologic context. The mechanism is real; the boundary of the evidence is the boundary of the claim.